Silk Road Medical's revenue for the
three
months ended in Mar. 2024 was €44.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €171.4 Mil.
Silk Road Medical's Revenue per Share for the
three
months ended in Mar. 2024 was €1.14.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €4.40.
During the past 12 months, the average Revenue per Share Growth Rate of Silk Road Medical was 15.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 26.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 25.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 7 years, Silk Road Medical's highest 3-Year average Revenue per Share Growth Rate was 56.70% per year. The lowest was 12.00% per year. And the median was 30.25% per year.
Silk Road Medical Revenue Historical Data
The historical data trend for Silk Road Medical's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's Revenue
For the Medical Devices subindustry, Silk Road Medical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Revenue distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Revenue falls into.
Silk Road Medical Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €171.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (FRA:2OW) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Silk Road Medical Revenue Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:2OW has been successfully added to your 